|
WO9724447A1
|
|
Immunostimulation mediated by gene-modified dendritic cells
|
|
WO9724452A2
|
|
Toxic-protein expressing viruses and producer cell lines
|
|
WO9723608A1
|
|
Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
|
|
WO9637626A1
|
|
Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein
|
|
WO9633281A1
|
|
High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
|
|
AU4690596A
|
|
Nucleic acid condensing agents with reduced immunogenicity
|
|
WO9621416A2
|
|
Methods and compositions for treatment of solid tumors in vivo
|
|
WO9621014A2
|
|
Production and administration of high titer recombinant retroviruses
|
|
AU4610396A
|
|
Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
|
|
WO9620732A2
|
|
Non-traumatic administration of gene delivery vehicles
|
|
AU4740096A
|
|
Direct administration of gene delivery vehicles at multiple sites
|
|
EP0797679A2
|
|
Recombinant alphavirus vectors
|
|
AU4594996A
|
|
Recombinant alphavirus vectors
|
|
WO9531566A1
|
|
Compositions and methods for targeting gene delivery vehicles
|
|
US6015686A
|
|
Eukaryotic layered vector initiation systems
|
|
US5681746A
|
|
Retroviral delivery of full length factor VIII
|
|
WO9510601A1
|
|
Methods for preserving recombinant viruses
|
|
WO9506717A2
|
|
Methods of suppressing graft rejection
|
|
WO9506718A2
|
|
Methods of suppressing autoimmune response
|
|
WO9506744A2
|
|
Methods of suppressing immune response by gene therapy
|
